{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myeloproliferative+Neoplasms+%28MPN%29&page=2", "query": { "condition": "Myeloproliferative Neoplasms (MPN)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myeloproliferative+Neoplasms+%28MPN%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-11T07:59:20.496Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06523556", "title": "Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Atypical Chronic Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm", "Recurrent Myelodysplastic/Myeloproliferative Neoplasm", "Recurrent Myeloproliferative Neoplasm", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Myelodysplastic/Myeloproliferative Neoplasm", "Refractory Myeloproliferative Neoplasm" ], "interventions": [ { "name": "Axatilimab", "type": "BIOLOGICAL" }, { "name": "Azacitidine", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Uma Borate", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2024-08-02", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-03-13", "last_synced_at": "2026-06-11T07:59:20.496Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT06523556" }, { "nct_id": "NCT01606579", "title": "Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "PRI-724", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prism Pharma Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 49, "start_date": "2012-07", "completion_date": "2016-12-30", "has_results": false, "last_update_posted_date": "2017-08-17", "last_synced_at": "2026-06-11T07:59:20.496Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Worcester, Massachusetts • Albuquerque, New Mexico + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "Albuquerque", "state": "New Mexico" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01606579" }, { "nct_id": "NCT07362225", "title": "MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Polycythemia Vera", "ET (Essential Thrombocythemia)", "Polycythemia Vera (PV)", "Essential Thrombocythemia (ET)", "Primary Myelofibrosis (MF)", "Primary Myelofibrosis (PMF)", "Myelofibrosis", "Myelofibrosis (MF)", "Myelofibrosis, Primary", "Myelofibrosis, Post ET", "Myelofibrosis, Post PV", "Myelofibrosis (PMF)", "Myelofibrosis，MF", "Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis", "Myelofibrosis Due to and Following Polycythemia Vera", "Myelofibrosis Transformation in Essential Thrombocythemia", "Myelofibrosis With High Molecular Risk Mutations", "MF", "Secondary Myelofibrosis", "Secondary Myelofibrosis in Myeloproliferative Disease", "Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)", "Post-Polycythemia Vera Myelofibrosis", "Post-polycythemia Vera Myelofibrosis (PPV-MF)", "Post-polycythemia Vera Myelofibrosis (Post-PV MF)", "Post-polycythemia Vera Myelofibrosis(Post-PV MF)", "Post-PV MF", "Post-Essential Thrombocythemia Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis (PET-MF)", "Post-essential Thrombocythemia Myelofibrosis(Post-ET MF)", "Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)", "Post-ET MF", "Pre-fibrotic Myelofibrosis", "Myeloproliferative Disorder", "Myeloproliferative Disorders", "Myeloproliferative Disorders (MPD)", "Myeloproliferative Neoplasms (MPNs)", "Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis", "Myeloproliferative Neoplasm With 10% Blasts or Higher", "Myeloproliferative Neoplasms", "MPN", "MPN (Myeloproliferative Neoplasms)", "MPN-associated Myelofibrosis", "Myeloproliferative Neoplasm, Unclassifiable", "Myeloproliferative Neoplasm, Not Otherwise Specified", "Accelerated Phase MPN", "Accelerated Phase Myeloproliferative Neoplasm", "Blast Phase MPN", "Blast Phase Myeloproliferative Neoplasm", "Thrombocythemia Myelofibrosis (PET-MF)", "Thrombocythemia, Essential", "Thrombocythemia, Hemorrhagic", "Agnogenic Myeloid Metaplasia", "Chronic Idiopathic Myelofibrosis", "Idiopathic Myelofibrosis", "MDS/MPN Crossover Syndromes" ], "interventions": [], "intervention_types": [], "sponsor": "MPN Research Foundation", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 5000, "start_date": "2025-09-26", "completion_date": "2035-09-08", "has_results": false, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-06-11T07:59:20.496Z", "location_count": 2, "location_summary": "Chicago, Illinois • New York, New York", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07362225" }, { "nct_id": "NCT02718300", "title": "A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MPN (Myeloproliferative Neoplasms)" ], "interventions": [ { "name": "Parsaclisib", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 74, "start_date": "2017-02-08", "completion_date": "2022-04-29", "has_results": true, "last_update_posted_date": "2024-05-01", "last_synced_at": "2026-06-11T07:59:20.496Z", "location_count": 39, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Berkeley, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02718300" }, { "nct_id": "NCT02775383", "title": "The National Myelodysplastic Syndromes (MDS) Study", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Myelodysplastic Syndromes (MDS)" ], "interventions": [ { "name": "Therapeutic", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2115, "start_date": "2016-06-13", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-02-03", "last_synced_at": "2026-06-11T07:59:20.496Z", "location_count": 280, "location_summary": "Anaheim, California • Baldwin Park, California • Bellflower, California + 213 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Fontana", "state": "California" }, { "city": "Harbor City", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02775383" }, { "nct_id": "NCT01351545", "title": "A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hematologic Malignancies", "Inherited Disorders of Metabolism", "Inherited Abnormalities of Platelets", "Histiocytic Disorders", "Acute Myelogenous Leukemia (AML or ANLL)", "Acute Lymphoblastic Leukemia (ALL)", "Other Acute Leukemia", "Chronic Myelogenous Leukemia (CML)", "Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases", "Other Leukemia", "Hodgkin Lymphoma", "Non-hodgkin Lymphoma", "Multiple Myeloma/ Plasma Cell Disorder (PCD)", "Inherited Abnormalities of Erythrocyte Differentiation or Function", "Disorders of the Immune System", "Autoimmune Diseases", "Severe Aplastic Anemia" ], "interventions": [ { "name": "A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Center for International Blood and Marrow Transplant Research", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 99999, "start_date": "2011-10", "completion_date": "2041-10", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-06-11T07:59:20.496Z", "location_count": 142, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01351545" }, { "nct_id": "NCT03755518", "title": "A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Myelofibrosis", "Post-Polycythemia Vera Myelofibrosis", "Myelofibrosis", "Post-essential Thrombocythemia Myelofibrosis" ], "interventions": [ { "name": "FEDRATINIB", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2019-03-27", "completion_date": "2023-11-08", "has_results": true, "last_update_posted_date": "2024-12-12", "last_synced_at": "2026-06-11T07:59:20.496Z", "location_count": 28, "location_summary": "Aurora, Colorado • Miami, Florida • Augusta, Georgia + 23 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03755518" }, { "nct_id": "NCT04285086", "title": "Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Essential Thrombocythemia" ], "interventions": [ { "name": "Ropeginterferon alfa-2b", "type": "BIOLOGICAL" }, { "name": "Anagrelide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "PharmaEssentia", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2020-08-25", "completion_date": "2029-08-31", "has_results": false, "last_update_posted_date": "2025-08-13", "last_synced_at": "2026-06-11T07:59:20.496Z", "location_count": 3, "location_summary": "St Louis, Missouri • Houston, Texas • Salt Lake City, Utah", "locations": [ { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04285086" }, { "nct_id": "NCT04064060", "title": "A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Myelodysplastic Syndromes (MDS)", "Beta-thalassemia", "Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis" ], "interventions": [ { "name": "Luspatercept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 665, "start_date": "2019-08-12", "completion_date": "2028-05-12", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-06-11T07:59:20.496Z", "location_count": 12, "location_summary": "Los Angeles, California • Oakland, California • Stanford, California + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04064060" }, { "nct_id": "NCT07143669", "title": "Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Clonal Mast Cell Disease", "KIT D816V Mutation", "Suspected KITD816V Mutated Clonal Mast Cell Disease" ], "interventions": [ { "name": "Screening", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Blueprint Medicines Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2025-10-17", "completion_date": "2028-10-31", "has_results": false, "last_update_posted_date": "2026-05-22", "last_synced_at": "2026-06-11T07:59:20.496Z", "location_count": 18, "location_summary": "Birmingham, Alabama • San Diego, California • Walnut Creek, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07143669" } ] }